Literature DB >> 29468467

Adverse effects associated with regadenoson myocardial perfusion imaging.

Efstathia Andrikopoulou1, Fadi G Hage2,3.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29468467     DOI： 10.1007/s12350-018-1218-7

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  48 in total

1.  Heart rate response to regadenoson: Making the case for its value in clinical practice.

Authors:  Efstathia Andrikopoulou; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2015-08-27       Impact factor: 5.952

2.  Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function.

Authors:  Toufigh Gordi; Brent Blackburn; Hsiao Lieu
Journal:  J Clin Pharmacol       Date:  2007-07       Impact factor: 3.126

3.  Complete heart block associated with regadenoson: a real side effect.

Authors:  Anil Pandit; Samuel Unzek Freiman
Journal:  J Nucl Cardiol       Date:  2012-08-23       Impact factor: 5.952

4.  A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging.

Authors:  Fadi G Hage; Phillip Dean; Fahad Iqbal; Jaekyeong Heo; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2011-07-22       Impact factor: 5.952

5.  The prognostic value of regadenoson myocardial perfusion imaging.

Authors:  Fadi G Hage; Gopal Ghimire; Davis Lester; Joshua Mckay; Steven Bleich; Stephanie El-Hajj; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2015-02-14       Impact factor: 5.952

6.  Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients.

Authors:  Deborah H Kwon; Manuel D Cerqueira; Ron Young; Penny Houghtaling; Elizabeth Lieber; Venu Menon; Richard C Brunken; Wael A Jaber
Journal:  J Nucl Cardiol       Date:  2010-04-23       Impact factor: 5.952

7.  Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial.

Authors:  Ami E Iskandrian; Timothy M Bateman; Luiz Belardinelli; Brent Blackburn; Manuel D Cerqueira; Robert C Hendel; Hsiao Lieu; John J Mahmarian; Ann Olmsted; S Richard Underwood; João Vitola; Whedy Wang
Journal:  J Nucl Cardiol       Date:  2007 Sep-Oct       Impact factor: 5.952

8.  Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial.

Authors:  Brian R Leaker; B O'Connor; Trevor T Hansel; Peter J Barnes; Lixen Meng; Vandana S Mathur; Hsiao D Lieu
Journal:  J Nucl Cardiol       Date:  2008-04-14       Impact factor: 5.952

9.  Adenosine-induced modulation of excitatory amino acid transport across isolated brain arterioles.

Authors:  Gerald A Grant; Joseph R Meno; Thien-Son Nguyen; Kathe A Stanness; Damir Janigro; Richard H Winn
Journal:  J Neurosurg       Date:  2003-03       Impact factor: 5.115

Review 10.  Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge.

Authors:  Yasmeen Golzar; Rami Doukky
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-01-22
View more
  2 in total

Review 1.  Review of cardiovascular imaging in the Journal of Nuclear Cardiology in 2017. Part 2 of 2: Myocardial perfusion imaging.

Authors:  Fadi G Hage; Wael A AlJaroudi
Journal:  J Nucl Cardiol       Date:  2018-04-16       Impact factor: 5.952

2.  Gender-related differences in side-effects and hemodynamic response to regadenoson in patients undergoing SPECT myocardial perfusion imaging.

Authors:  Athanasios Katsikis; Elena Kyrozi; Vasiliki Manira; Athanasios Theodorakos; Julia Malamitsi; Virginia Tsapaki; Ioannis Iakovou; Vasilios Voudris; Genovefa Kolovou; Maria Koutelou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-14       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.